Evommune shares plummeted 11.3% as its eczema drug failed to reach a major end in mid-term clinical trials.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.